NextPlat Corp Reports Q3 2025 Results with Improved Cost Management and Healthcare Recovery Trends

NextPlat Corp reported third-quarter 2025 financial results showing consolidated revenue of approximately $13.8 million compared to $15.4 million in the prior year period. The revenue decline primarily reflected lower 340B pharmacy contract revenue, though the company noted that late-quarter customer re-engagement efforts drove improving prescription volumes that are expected to continue into the fourth quarter. The company operates through its e-Commerce communications division and healthcare services through subsidiary Progressive Care.

Gross margin declined to 19.9% from 23.2% in the prior year quarter, reflecting lower margins in both Healthcare and e-commerce segments. This margin pressure was tied to reduced 340B revenue, new airtime costs, and temporary customer rate adjustments that affected profitability during the period. Despite these challenges, the company implemented significant cost control measures that showed meaningful results in the quarter's financial performance.

Operating expenses decreased substantially to approximately $4.7 million from $7.8 million in the prior year quarter, representing a significant improvement in operational efficiency. The reduction was driven by decreased stock-based compensation, executive compensation, and headcount reductions under companywide efficiency measures. These cost management initiatives contributed directly to the improved bottom-line results and demonstrate the company's focus on sustainable operations.

The company reported a reduced net loss of approximately $2.2 million, or ($0.08) per diluted share, compared to a loss of $4.2 million, or ($0.22) per diluted share, in the same period last year. This represents a 48% improvement in net loss and significant per-share improvement, reflecting the combined impact of cost reductions and operational improvements. The improving trend in prescription volumes toward the end of the quarter suggests potential for continued recovery in the healthcare segment.

NextPlat ended the quarter with $13.9 million in cash and repurchased 130,549 shares during the period, indicating confidence in the company's valuation and financial stability. The share repurchase activity demonstrates management's belief in the long-term value proposition despite current market challenges. Additional information about the company's performance is available in their newsroom at https://ibn.fm/NXPL.

The quarterly results highlight the ongoing transformation within NextPlat's operations as the company navigates challenging market conditions while maintaining financial discipline. The improving prescription volume trends in the healthcare segment, combined with substantial cost reductions, position the company for potential recovery in future quarters. Investors and industry observers will be watching closely to see if the late-quarter momentum continues into the fourth quarter and whether the cost management initiatives can be sustained while driving revenue growth.